MAT2A inhibitors, such as SCR-7952, show strong and selective anti-tumor activity in both in vitro and in vivo models of MTAP-deficient cancer, and can produce synergistic antitumor effects when used competitively or cooperatively with S-AdenosylMethionine and PRMT 5 inhibitors [113]. Here, MTAP is linked to cancer.